The weight loss drug landscape is moving fast. Semaglutide (Ozempic/Wegovy) seemed revolutionary in 2021. Tirzepatide (Mounjaro/Zepbound) surpassed it in 2022-2023 clinical trials. Now there's retatrutide — a triple agonist from Eli Lilly that's posting numbers that would have seemed impossible a few years ago.
Here's what we know about where the science is going.
What Is Retatrutide?
Retatrutide (development code LY3437943) is a once-weekly injectable drug developed by Eli Lilly. What makes it different from current medications:
- Semaglutide (Ozempic, Wegovy): GLP-1 receptor agonist — one target
- Tirzepatide (Mounjaro, Zepbound): GLP-1 + GIP receptor agonist — two targets
- Retatrutide: GLP-1 + GIP + glucagon receptor agonist — three targets
The addition of glucagon receptor agonism is the key innovation. Glucagon receptor activation increases energy expenditure and fatty acid oxidation — in theory, you're not just eating less, you're burning more efficiently.
What the Clinical Trial Data Shows
The Phase 2 trial results published in the New England Journal of Medicine (2023) were striking:
At the highest dose (12mg weekly) at 48 weeks: - Mean weight loss: 24.2% - 83% of participants achieved ≥10% weight loss - 62% achieved ≥15% weight loss - Some participants achieved 30%+ body weight loss
To put that in context: bariatric surgery (sleeve gastrectomy) typically produces 25-30% total body weight loss over 12-18 months. Retatrutide in a Phase 2 trial at 48 weeks approached that threshold.
Tirzepatide, the current best-in-class, produced about 20-22% at similar timepoints in its pivotal trials. Retatrutide appears to offer a meaningful step-up in efficacy.
The Side Effect Profile
Not surprisingly, more receptor activity means more GI side effects. In Phase 2:
- Nausea: ~60% at some point during the trial
- Vomiting: ~30%
- Diarrhea: ~28%
- Constipation: ~24%
The pattern is familiar — same GLP-1-class GI profile, somewhat amplified. The clinical trial used careful dose escalation to manage tolerability. Discontinuation rates due to adverse events were around 16% at the highest dose — higher than tirzepatide (~4-5%) but comparable side effects to semaglutide at maximum dose.
Other observations: - Modest increases in heart rate (similar to other GLP-1 drugs) - Reduction in cholesterol and triglycerides - Improvements in fasting glucose
The Cardiovascular Angle
One significant unknown about GLP-1 + glucagon co-agonism is cardiovascular impact. Pure GLP-1 agonists (semaglutide) have demonstrated cardiovascular benefit in landmark trials (SUSTAIN-6, SELECT). Tirzepatide's cardiovascular data is emerging. Retatrutide's cardiovascular profile will need dedicated outcomes trials before it can be positioned as cardioprotective — the glucagon component raises questions that need resolution.
What's the Current Status?
As of early 2026, retatrutide is in Phase 3 clinical trials — the final stage before FDA approval. Eli Lilly has multiple ongoing Phase 3 studies evaluating retatrutide for: - Obesity (the core indication) - Type 2 diabetes - Non-alcoholic fatty liver disease (MASLD/MASH)
If Phase 3 results hold and the FDA review proceeds normally, retatrutide could reach approval in 2025-2027. Exact timing depends on trial completion, FDA priority review status, and whether any safety signals emerge in the larger dataset.
How Does It Compare to What's Available Now?
| Drug | Targets | Avg. Weight Loss | Status | |------|---------|-----------------|--------| | Semaglutide 2.4mg | GLP-1 | ~15% | Approved (Wegovy) | | Tirzepatide 15mg | GLP-1 + GIP | ~22% | Approved (Zepbound) | | Retatrutide 12mg | GLP-1 + GIP + GCG | ~24% | Phase 3 |
The marginal gain from tirzepatide to retatrutide (~2-4%) is meaningful at a population level but less dramatic than the jump from semaglutide to tirzepatide (~7%). The bigger question is how retatrutide performs in real-world patients outside optimized clinical trial conditions, and whether the slightly higher GI side effect burden affects tolerability.
What About Cagrilintide/Semaglutide (CagriSema)?
Worth mentioning in the same breath: Novo Nordisk is developing a co-formulation of semaglutide + cagrilintide (an amylin analog), which showed ~25% weight loss in Phase 3 results announced in late 2024/2025 — comparable numbers to retatrutide. This suggests 2026-2028 will feature a genuine competition between next-generation agents for the best weight loss outcome.
Should You Wait for Retatrutide?
For most people who need weight loss treatment: no.
Tirzepatide is currently available, highly effective, and well-characterized. The incremental efficacy gain of retatrutide (if Phase 3 confirms Phase 2) is modest versus waiting 1-2 years. If you have a clinical need for treatment now, starting with what's available is the right call — you can always transition to a superior agent when available.
For people who have tried and failed to get adequate results with tirzepatide at 15mg: retatrutide (when available) represents a meaningful therapeutic option. This is the patient population that will benefit most.
The Compounded Retatrutide Question
As soon as clinical data gets attention, peptide/compounding markets react. You may have seen "retatrutide" offered through compounding pharmacies or research peptide suppliers. This is not the same molecule tested in Eli Lilly's clinical trials — synthesis quality, purity, formulation, and dosing are unverified and unstandardized. The FDA has not approved retatrutide, and without an FDA-approved shortage designation, compounding of unapproved drugs for weight loss is legally and clinically problematic.
The responsible answer: wait for the approved product.
Frequently Asked Questions
What is retatrutide?
Retatrutide (LY3437943) is a once-weekly injectable drug developed by Eli Lilly that activates three hormone receptors: GLP-1, GIP, and glucagon. This triple agonism makes it the most potent weight loss medication in late-stage clinical development, with Phase 2 trials showing approximately 24% body weight loss at 48 weeks — approaching bariatric surgery outcomes.
When will retatrutide be FDA approved?
As of early 2026, retatrutide is in Phase 3 clinical trials. If those trials confirm Phase 2 results and the FDA review proceeds normally, approval could come in 2026-2027. There is no confirmed approval date; exact timing depends on trial completion and FDA review timelines.
Is retatrutide better than tirzepatide?
Phase 2 data suggests retatrutide produces modestly better weight loss than tirzepatide (~24% vs ~22% at comparable timepoints), though direct head-to-head Phase 3 comparisons don't yet exist. Retatrutide may also have a somewhat higher GI side effect burden due to the additional glucagon receptor activity. Whether the efficacy difference is clinically meaningful for an individual patient depends on their specific goals and tolerability.
Can I get retatrutide now?
Retatrutide is not FDA-approved as of early 2026. It is not legally available through licensed prescribers. Some compounding pharmacies and research peptide suppliers market substances called 'retatrutide,' but these are unverified products without the quality control, dosing validation, or safety data of the clinical trial compound. The responsible option is to wait for the FDA-approved product.
How does retatrutide work for weight loss?
Retatrutide activates three receptors simultaneously: GLP-1 (reduces appetite, slows gastric emptying), GIP (modulates insulin and fat metabolism), and glucagon (increases energy expenditure and fat oxidation). The combination theoretically produces greater weight loss than single or dual agonists by addressing multiple aspects of energy balance — reduced intake via appetite suppression AND increased expenditure via the glucagon component.
Get our free Body Composition Guide
Protein protocols, workout structure, sleep optimization, and the supplement stack that actually works.
Get our free Body Composition Guide →
